Published online May 27, 2014. doi: 10.4254/wjh.v6.i5.315
Revised: March 10, 2014
Accepted: April 16, 2014
Published online: May 27, 2014
Processing time: 175 Days and 9.5 Hours
Core tip: While nucleos(t)ide analogs (NAs) offer a benign course in patients with hepatitis B virus before and after liver and renal transplantation, there is still scope for improvement. The administration of high genetic barrier NAs such as entecavir or tenofovir pre-transplant and the careful patient selection for hepatitis virus immunoglobulin-free regimens post-transplant contribute to improved medical care and facilitate its provision from a practical standpoint. Concordantly, attention has turned to new treatment strategies regarding hepatitis C virus recurrence after liver and renal transplantation. The addition of oral direct acting antivirals to the existing treatment marks a promising strategy for prognosis amelioration of these patients.